Compare · BTI vs MDWD
BTI vs MDWD
Side-by-side comparison of British American Tobacco Industries p.l.c. (BTI) and MediWound Ltd. (MDWD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BTI and MDWD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- BTI is the larger of the two at $133.09B, about 749.7x MDWD ($177.5M).
- Over the past year, BTI is up 34.4% and MDWD is down 37.8% - BTI leads by 72.2 points.
- BTI has been more active in the news (6 items in the past 4 weeks vs 4 for MDWD).
- BTI has more recent analyst coverage (14 ratings vs 8 for MDWD).
- Company
- British American Tobacco Industries p.l.c.
- MediWound Ltd.
- Price
- $61.00-1.31%
- $13.85-3.32%
- Market cap
- $133.09B
- $177.5M
- 1M return
- +3.74%
- -16.19%
- 1Y return
- +34.39%
- -37.83%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 1998
- 2014
- News (4w)
- 6
- 4
- Recent ratings
- 14
- 8
British American Tobacco Industries p.l.c.
British American Tobacco p.l.c. provides tobacco and nicotine products to consumers worldwide. It offers vapour products, tobacco heating products, and modern oral products; combustible products; and traditional oral products, such as Swedish-style snus and American moist snuff. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Latest BTI
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- Large owner Bt De Investments Inc. converted options into 95,281,277 shares and was granted 14,662,765 shares (SEC Form 4)
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form SCHEDULE 13G filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
- SEC Form 6-K filed by British American Tobacco Industries p.l.c.
Latest MDWD
- Director Rubinstein Samuel bought $2,150 worth of Ordinary Shares (150 units at $14.33), increasing direct ownership by 5% to 2,993 units (SEC Form 4)
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- SEC Form SCHEDULE 13G filed by MediWound Ltd.
- MediWound to Report First Quarter 2026 Financial Results
- SEC Form 6-K filed by MediWound Ltd.
- Newly Published U.S. Expert Consensus Aligns with MediWound's Strategy for Chronic Wound Debridement
- MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million